静脉羧基麦芽糖铁改善射血分数保留心衰合并铁缺乏患者的运动能力:FAIR-HFpEF 试验
FAIR-HFpEF 为多中心随机双盲试验,计划纳入 200 例有症状的射血分数保留心衰(HFpEF)合并铁缺乏患者,比较静脉羧基麦芽糖铁(FCM)与安慰剂对 6 分钟步行试验距离(6MWTD)的影响。因招募缓慢,仅纳入 39 例即终止(中位年龄 80 岁,62% 女性)。
要点
- 在 HFpEF 合并铁缺乏患者中,静脉 FCM 使第 24 周 6MWTD 较安慰剂改善 49 m。
- FCM 组严重不良事件少于安慰剂组,率比 0.27。
- 试验因招募缓慢提前终止,不足以判断对症状或生活质量的影响。
核心结论
- 在 HFpEF 合并铁缺乏标志物的患者中,静脉 FCM 改善 6MWTD 并与更少严重不良事件相关。
- 该试验缺乏足够把握度来识别或排除对症状或生活质量的影响。
研究设计与样本
- 多中心、随机、双盲试验,设计比较静脉 FCM 与安慰剂(生理盐水)在 200 例有症状 HFpEF 合并铁缺乏患者中的效果。
- 铁缺乏定义为血清铁蛋白 <100 ng/mL,或铁蛋白 100–299 ng/mL 且转铁蛋白饱和度 <20%。
- 主要终点为基线至第 24 周 6MWTD 的变化。
- 因招募缓慢,纳入 39 例后试验终止(中位年龄 80 岁,62% 女性)。
主要发现
- 次要终点包括 NYHA 分级、患者总体评估和健康相关生活质量的变化,组间差异均无统计学意义。
- 总不良事件数 FCM 组为 76 例,安慰剂组为 114 例。
临床怎么用
- 对 HFpEF 合并铁缺乏(血清铁蛋白 <100 ng/mL 或铁蛋白 100–299 ng/mL 且转铁蛋白饱和度 <20%)的患者,可考虑静脉 FCM 以改善运动能力。
- 静脉铁对症状和生活质量的影响尚不明确,需在更大队列中进一步研究。
局限性
- 试验因招募缓慢提前终止,仅纳入 39 例,缺乏足够把握度识别或排除对症状或生活质量的影响。
- 样本量小且中位年龄 80 岁、62% 女性,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF). METHODS: FAIR-HFpEF was a multicentre, randomized, double-blind trial designed to compare intravenous ferric carboxymaltose (FCM) with placebo (saline) in 200 patients with symptomatic HFpEF and ID (serum ferritin < 100 ng/mL or ferritin 100-299 ng/mL with transferrin saturation < 20%). The primary endpoint was change in 6-min walking test distance (6MWTD) from baseline to week 24. Secondary endpoints included changes in New York Heart Association class, patient global assessment, and health-related quality of life (QoL). RESULTS: The trial was stopped because of slow recruitment after 39 patients had been included (median age 80 years, 62% women). The change in 6MWTD from baseline to week 24 was greater for those assigned to FCM compared to placebo [least square mean difference 49 m, 95% confidence interval (CI) 5-93; P = .029]. Changes in secondary endpoints were not significantly different between groups. The total number of adverse events (76 vs. 114) and serious adverse events (5 vs. 19; rate ratio 0.27, 95% CI 0.07-0.96; P = .043) was lower with FCM than placebo. CONCLUSIONS: In patients with HFpEF and markers of ID, intravenous FCM improved 6MWTD and was associated with fewer serious adverse events. However, the trial lacked sufficient power to identify or refute effects on symptoms or QoL. The potential benefits of intravenous iron in HFpEF with ID should be investigated further in a larger cohort.
引用
- von Haehling, Doehner, Evertz, et al. Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J. 2024. PMID: 39185895. doi:10.1093/eurheartj/ehae479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。